^
13d
upreACH-2: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia (clinicaltrials.gov)
P2, N=16, Terminated, Sanofi | Active, not recruiting --> Terminated; Sponsor decision. Not related to safety concern.
Trial termination
|
FGFR3 mutation
15d
RAGNAR: A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (clinicaltrials.gov)
P2, N=316, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2025 --> Dec 2025
Trial completion date
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR (Fibroblast Growth Factor Receptor) • TACC3 (Transforming acidic coiled-coil containing protein 3) • TACC2 (Transforming Acidic Coiled-Coil Containing Protein 2)
|
FGFR3 mutation • FGFR mutation • FGFR fusion
|
Balversa (erdafitinib)
23d
Biological and therapeutic implications of FGFR alterations in urothelial cancer: A systematic review from non-muscle-invasive to metastatic disease. (PubMed, Actas Urol Esp (Engl Ed))
Two phase 3 trials are currently evaluating the intravesical device system (TAR210) in FGFR-altered intermediate NMIBC (MoonRISe-1) and infigratinib in the adjuvant setting of high-risk of recurrence patients with MIBC or UTUC (PROOF-302)...Nine phase 1b/2 trials are focusing on the combination of FGFR inhibitors with ICIs, chemotherapy, or enfortumab vedotin...However, no phase 3 trial is terminated, so there is currently no level 1 evidence with long-term outcomes to support the combination of FGFR inhibitors with ICIs, chemotherapy, or targeted therapies. A better understanding of the different mechanisms of action to inhibit FGFR signaling pathways, optimal patient selection and treatment approaches is still needed.
Journal • IO biomarker
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR (Fibroblast Growth Factor Receptor)
|
FGFR3 mutation
|
Truseltiq (infigratinib) • Padcev (enfortumab vedotin-ejfv) • erdafitinib intravesical delivery system (TAR-210)
27d
Extreme Morphology and Metabolic Health (clinicaltrials.gov)
P=N/A, N=102, Active, not recruiting, University of Bath | Recruiting --> Active, not recruiting
Enrollment closed
|
FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR3 mutation
1m
BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder (clinicaltrials.gov)
P=N/A, N=4, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2025 --> Jan 2026
Trial completion date • Trial primary completion date
|
FGFR3 mutation
|
Truseltiq (infigratinib)
1m
Updates on Urothelial Carcinoma of the Upper Urinary Tract with a Focus on Molecular Findings. (PubMed, Surg Pathol Clin)
Current treatments emphasize platinum-based chemotherapy post-surgery, though immunotherapy shows promise, especially in LS cases. Further molecular insights are crucial for improving diagnosis and treatment.
Review • Journal • IO biomarker
|
TP53 (Tumor protein P53) • FGFR3 (Fibroblast growth factor receptor 3)
|
TP53 mutation • FGFR3 mutation
1m
upreACH-2: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia (clinicaltrials.gov)
P2, N=16, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting | N=36 --> 16 | Trial completion date: Dec 2027 --> Feb 2025 | Trial primary completion date: Dec 2027 --> Feb 2025
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
FGFR3 mutation
1m
Oncogenic Human Papillomaviruses Drive One-Third of Sinonasal Squamous Cell Carcinoma and Are Not Mutually Exclusive for Gene Mutations. (PubMed, Head Neck)
One-third of SNSCCs were high-risk HPV driven lesions. However, gene mutations and HR-HPV infections are not mutually exclusive. Further studies are required to analyze the prognostic value of these associations.
Journal
|
EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR3 (Fibroblast growth factor receptor 3) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
|
TP53 mutation • EGFR mutation • PIK3CA mutation • FGFR3 mutation
2ms
Comprehensive genomic characterization of early-stage bladder cancer. (PubMed, Nat Genet)
Finally, integrative clustering of multi-omics data highlighted the important role of genomic instability and immune cell exhaustion in disease aggressiveness. These findings advance our understanding of genomic differences associated with disease aggressiveness in NMIBC and may ultimately improve patient stratification.
Journal
|
TP53 (Tumor protein P53) • FGFR3 (Fibroblast growth factor receptor 3)
|
TP53 mutation • FGFR3 mutation
2ms
Passing the Torch forward: Moving beyond EGFR Inhibition in NMIBC Prevention. (PubMed, Cancer Prev Res (Phila))
Utilizing a "window-of-opportunity" design, erlotinib was evaluated for its effect on EGFR phosphorylation, although the unconventional dosing regimen failed to demonstrate efficacy...A future trial design could focus on clinical outcomes such as tumor response and NMIBC recurrence while also evaluating FGFR3 inhibition in both tumor and adjacent normal bladder epithelia. See related article by Downs et al., p. 31.
Journal
|
EGFR (Epidermal growth factor receptor) • FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR3 mutation
|
erlotinib
2ms
AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer. (PubMed, Nat Commun)
Selective targeting of FGFR3 hotspot mutations with tyrosine kinase inhibitors (e.g., erdafitinib) is approved for mUC and requires FGFR3 mutational testing...Encompassing 1222 cases, our study is a large-scale validation of a model prescreening FGFR3 mutations for MIBC and mUC patients. In this work, we demonstrate that our model achieves high sensitivity (>93%) on advanced and metastatic cases while reducing molecular testing by 40% on average, thereby offering a cost-effective and rapid pre-screening tool for identifying patients eligible for FGFR3 targeted therapies.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR3 mutation
|
Balversa (erdafitinib)
3ms
BISCAY: Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (clinicaltrials.gov)
P1, N=117, Active, not recruiting, AstraZeneca | Trial completion date: Jun 2024 --> Mar 2025
Trial completion date
|
HRD (Homologous Recombination Deficiency) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • FGFR (Fibroblast Growth Factor Receptor) • CD8 (cluster of differentiation 8) • CCNE1 (Cyclin E1) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor)
|
PD-L1 expression • FGFR3 mutation • CDKN2A deletion • CCNE1 amplification • CDKN2A mutation • FGFR fusion • RB1 deletion • MYCL amplification
|
Lynparza (olaparib) • Imfinzi (durvalumab) • Koselugo (selumetinib) • adavosertib (AZD1775) • fexagratinib (ABSK091) • vistusertib (AZD2014) • danvatirsen (AZD9150)
3ms
Diagnostic and prognostic genomic aberrations in upper tract urothelial carcinoma can be identified in focal barbotage samples. (PubMed, BJU Int)
Focal barbotage samples enable identification of gene mutations and other genetic aberrations that may add important prognostic information to histopathology and cytology. Refined prognostication of UTUC patients already at diagnosis can guide treatment decisions and follow-up programmes.
Journal
|
TP53 (Tumor protein P53) • FGFR3 (Fibroblast growth factor receptor 3) • ARID1A (AT-rich interaction domain 1A) • MDM2 (E3 ubiquitin protein ligase) • KMT2D (Lysine Methyltransferase 2D) • KDM6A (Lysine Demethylase 6A)
|
TP53 mutation • FGFR3 mutation
4ms
Expert Consensus on the Diagnosis and Treatment of FGFR Gene-Altered Solid Tumors. (PubMed, Glob Med Genet)
For example, erdafitinib is approved for treating locally advanced or metastatic urothelial cancer patients with FGFR2/FGFR3 mutations, and pemigatinib is approved for treating cholangiocarcinoma with FGFR2 fusion/rearrangement. Various detection methods, such as polymerase chain reaction, next-generation sequencing, fluorescence in situ hybridization, and immunohistochemistry, are available, and their selection should be based on diagnostic and treatment decision-making needs. Our developed expert consensus aims to standardize the diagnosis and treatment process for FGFR gene mutations and facilitate the practical application of FGFR inhibitors in clinical practice.
Review • Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR (Fibroblast Growth Factor Receptor)
|
FGFR2 mutation • FGFR2 fusion • FGFR3 mutation
|
Balversa (erdafitinib) • Pemazyre (pemigatinib)
4ms
FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development. (PubMed, J Korean Med Sci)
Among these therapies, erdafitinib, a pan-fibroblast growth factor receptor (FGFR) inhibitor for specific FGFR2 and FGFR3 alterations, is the only targeted therapy approved till now...Ongoing investigations exist on its use in non-muscle-invasive BC and in combination with drugs such as enfortumab vedotin in mUC...This review emphasizes the importance of FGFR inhibition in UC and the optimization of its use in clinical practice. Moreover, it underscores the ongoing efforts to evaluate combination strategies and early treatment testing to enhance the effectiveness of targeted therapies for UC.
Review • Journal • IO biomarker
|
TP53 (Tumor protein P53) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • RB1 (RB Transcriptional Corepressor 1)
|
TP53 mutation • FGFR2 mutation • FGFR3 mutation
|
Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)
4ms
A Molecular Urine Assay to Detect Recurrences During Surveillance of High-Risk Non-Muscle Invasive Bladder Cancer. (PubMed, Bladder Cancer)
This study validates the performance of a previously developed urine assay in an unselected cohort of HR-NMIBC patients under surveillance. With a robust sensitivity/specificity and a strong anticipatory effect, this assay proves a useful adjunct ready for evaluation in a future randomized controlled trial.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3) • TERT (Telomerase Reverse Transcriptase)
|
FGFR3 mutation • TERT mutation
4ms
TAS-120-203: Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma (clinicaltrials.gov)
P2, N=43, Active, not recruiting, Taiho Oncology, Inc. | Trial primary completion date: Aug 2025 --> Mar 2024
Trial primary completion date • Metastases
|
FGFR3 mutation • FGFR1 mutation • FGFR1 fusion • FGFR3 fusion
|
Keytruda (pembrolizumab) • Lytgobi (futibatinib)
4ms
Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer. (PubMed, Nat Rev Urol)
The characterization of metastatic tumour samples can improve response prediction to immunotherapy, the anti-NECTIN4 antibody-drug conjugate enfortumab vedotin and the FGFR inhibitor erdafitinib. Routine metastatic biopsy can thus improve the precision of identifying driver druggable alterations, thus improving treatment selection for patients with mUC.
Review • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases • Biopsy
|
FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR3 mutation • PD-L1 mutation
|
Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)
5ms
MTAP protein status is highly concordant with CDKN2A fluorescent in situ hybridization and allows stratification of the luminal subtype in muscle-invasive bladder cancer. (PubMed, Histopathology)
Our findings highlight CDKN2A HD and MTAP loss as prevalent genetic alterations in MIBC and mUC, particularly within the luminal-URO subtype and FGFR3-mutated, p53-normal/wildtype tumours. MTAP IHC can serve as a surrogate marker for 9p21.3 HD, highlighting its clinical relevance and potential as a therapeutic target and predictive biomarker in MIBC.
Journal • Discordant
|
TP53 (Tumor protein P53) • FGFR3 (Fibroblast growth factor receptor 3) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MTAP (Methylthioadenosine Phosphorylase)
|
TP53 mutation • TP53 wild-type • FGFR3 mutation • CDKN2A deletion • CDKN2A deletion + MTAP deletion
6ms
Evaluation of a cytology-molecular co-test in liquid-based cytology-processed urine for defining indeterminate categories of the Paris system. (PubMed, Acta Cytol)
This pilot study suggests that the incorporation of FGFR3/pTERT molecular testing in urine LBC could enhance the diagnostic value of cytology by diagnosing BUC in indeterminate cytology categories.
Journal • Cytology
|
FGFR3 (Fibroblast growth factor receptor 3) • TERT (Telomerase Reverse Transcriptase)
|
FGFR3 mutation • TERT mutation
6ms
Early Optical Coherence Tomography Signs of Erdafitinib-Induced Retinopathy. (PubMed, Cureus)
The drug may exert toxic effects on retinal pigment epithelium, which may be seen through interval OCTs and visualization of the interdigitation zone. Therefore, pronunciation of the ellipsoid and interdigitation zone on OCT may allow for surveillance of early manifestations of erdafitinib-induced retinal toxicity.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR2 mutation • FGFR3 mutation
|
Balversa (erdafitinib)
6ms
Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia. (PubMed, J Med Chem)
The pan-FGFR inhibitor erdafitinib was approved for the treatment of mUC with FGFR3 alterations but is limited due to FGFR isoform off-target toxicities and the development of on-target gatekeeper resistance mutations. TYRA-300 (22) was conceived using a structure-based approach as a potent FGFR3-selective inhibitor to avoid the toxicities associated with inhibition of FGFR1, FGFR2, and FGFR4, and to be agnostic for the FGFR3 gatekeeper mutations. TYRA-300 is being evaluated in a Phase 1 clinical trial in urothelial cancers and solid tumors, with intention to initiate Phase 2 studies in urothelial cancers and achondroplasia.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR4 (Fibroblast growth factor receptor 4)
|
FGFR2 mutation • FGFR3 mutation • FGFR mutation • FGFR3 G380R
|
Balversa (erdafitinib) • TYRA-300
6ms
Analytic validation of an FGFR -focused cell-free DNA liquid biopsy assay (FGFR-Dx). (PubMed, medRxiv)
Custom FGFR synthetic reference standards representing both single nucleotide variants (SNVs) and gene rearrangements were utilized at a range of variant frequencies and revealed a detection limit of 0.5% with sensitivities of 97.2% and 92.9% for SNVs and rearrangements, respectively. Furthermore, FGFR-Dx detected rearrangements and identified the intronic breakpoints from cfDNA collected from 13 of 15 patients with known FGFR fusions.
Journal • Liquid biopsy • Biopsy
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor)
|
FGFR2 mutation • FGFR3 mutation • FGFR fusion • FGFR2 rearrangement
8ms
FGFR alterations in a contemporary real-world cohort of advanced or metastatic urothelial carcinoma (ECP 2024)
Based on reflex molecular analysis performed on consecutive advanced/metastatic BCs, we found FGFR alterations to be present in approximately 17% of UCs, with FGFR3 being more frequently altered than FGFR1 and FGFR2 genes. These patients could gain clinical benefits from receiving a FGFR inhibitor such as erdafitinib which is an approved drug to treat FGFR-altered BCs lacking response to chemotherapy. Future studies will include a larger cohort to assess the correlation of FGFR alterations with histologic subtypes of invasive UC.
Real-world evidence • Clinical • Real-world • Metastases
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor)
|
FGFR1 amplification • FGFR2 mutation • FGFR2 fusion • FGFR3 mutation • FGFR mutation • FGFR3 fusion
|
Oncomine™ Comprehensive Assay v3M • Oncomine™ Comprehensive Assay Plus
|
Balversa (erdafitinib)
8ms
Detection of FGFR3 mutations and fusions in bladder cancer samples: Comparison of the MODAPLEX FGFR panel with therascreen FGFR Kit (ECP 2024)
The MODAPLEX FGFR panel allows the stratification of bladder cancer patients by determination of the FGFR3 mutational and FGFR2/3 fusion status. The PCR-based FGFR assessment by MODAPLEX FGFR panel and therascreen FGFR kit is highly concordant (78/79). The MODAPLEX assays enable fast, local FGFR assessment in a multiplexed one-step approach within few hours.
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • TACC3 (Transforming acidic coiled-coil containing protein 3)
|
FGFR2 mutation • FGFR2 fusion • FGFR3 mutation • FGFR3 S249C • FGFR3 Y373C • FGFR3 fusion • FGFR3 G370C • FGFR3 R248C • FGFR3 K650E
|
Uromonitor®
10ms
Patient with mediastinal carcinoma of unknown primary with RET fusion achieves durable response with RET inhibition. (PubMed, Anticancer Drugs)
The patient was initiated on selpercatinib, which was held after 3 weeks due to thrombocytopenia and hypertension. Pralsetinib was held during adjuvant chemoradiation for the GBM, and again for 4 weeks due to pneumonitis that resolved with steroids, and pralsetinib was restarted at a reduced dose. The patient has since demonstrated a stable reduction of the mediastinal mass for >15 months with RET inhibition therapy, despite several treatment interruptions.
Journal • PD(L)-1 Biomarker • IO biomarker
|
TP53 (Tumor protein P53) • RET (Ret Proto-Oncogene) • FGFR3 (Fibroblast growth factor receptor 3) • TERT (Telomerase Reverse Transcriptase) • TACC3 (Transforming acidic coiled-coil containing protein 3) • CCDC6 (Coiled-Coil Domain Containing 6)
|
TP53 mutation • RET fusion • FGFR3-TACC3 fusion • FGFR3 mutation • CCDC6-RET fusion • FGFR3 fusion • TERT mutation • TERT 124C>T
|
Retevmo (selpercatinib) • Gavreto (pralsetinib)
11ms
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression. (PubMed, Blood Cancer J)
Importantly, novel potential predictors of treatment resistance were identified: NRAS mutations and the co-occurrence of t(4;14) plus FGFR3 mutations were associated with an increased risk of biological progression. In conclusion, we have carried out for the first time a molecular characterization of HR SMM patients treated with an intensive regimen, identifying genomic predictors of poor outcomes in this setting.
Clinical Trial,Phase II • Journal
|
NRAS (Neuroblastoma RAS viral oncogene homolog) • FGFR3 (Fibroblast growth factor receptor 3) • TENT5C (Terminal Nucleotidyltransferase 5C)
|
NRAS mutation • FGFR3 mutation • Chr t(4;14) • TENT5C mutation
11ms
Muscle-Invasive Bladder Cancer With Hydronephrosis Exhibits a High Frequency of Mutations in Fibroblast Growth Factor Receptor 3 Gene. (PubMed, Anticancer Res)
MIBC presenting HN exhibits a high frequency of mutations in the FGFR3 gene. In addition, not HN itself, but reduced renal function due to HN may worsen the prognosis for MIBC.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR3 mutation
11ms
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR3 mutation
11ms
TAS-120-203: Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma (clinicaltrials.gov)
P2, N=46, Active, not recruiting, Taiho Oncology, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2023 --> May 2024
Enrollment closed • Trial primary completion date • Metastases
|
FGFR3 mutation • FGFR1 mutation • FGFR1 fusion • FGFR3 fusion
|
Keytruda (pembrolizumab) • Lytgobi (futibatinib)
11ms
Advances in preclinical assessment of therapeutic targets for bladder cancer precision medicine. (PubMed, Curr Opin Urol)
Several novel preclinical targets and treatment options have been described recently. The validation of these advances will lead to the development and implementation of robust personalized treatment regimens for bladder cancer patients.
Preclinical • Journal • IO biomarker
|
FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR3 mutation
11ms
FGFR3 Mutations in Urothelial Carcinoma: A Single-Center Study Using Next-Generation Sequencing. (PubMed, J Clin Med)
Our results revealed that FGFR3 mutations were more prevalent in patients with NMIBC and lower stage UC and associated with a high-risk of NMIBC. Large multicenter studies are needed to clarify the clinical significance of FGFR3 mutations in UC.
Journal • Next-generation sequencing
|
FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR3 mutation
11ms
Phase classification • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2)
|
HER-2 negative • FGFR1 amplification • FGFR2 mutation • FGFR2 fusion • FGFR3 mutation • FGFR fusion • FGFR1 fusion • FGFR3 fusion
|
Tecentriq (atezolizumab) • paclitaxel • Cyramza (ramucirumab) • derazantinib (ARQ 087)
11ms
Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis. (PubMed, Int J Surg)
This meta-analysis demonstrates a strong association of ctDNA status and its dynamic change with survival outcomes in UC, suggesting substantial clinical utility of ctDNA testing in prognosis prediction and decision making in this setting.
Retrospective data • Review • Journal • IO biomarker • Circulating tumor DNA
|
FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR3 mutation
12ms
Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model. (PubMed, Front Immunol)
These results indicate the need to quantify FGFR3 signaling and the fitness advantage conferred on bladder cancer cells harboring this mutation. This ABM approach may enable rationally designed treatment plans to improve clinical outcomes.
Journal • PD(L)-1 Biomarker • IO biomarker
|
FGFR3 (Fibroblast growth factor receptor 3) • CD8 (cluster of differentiation 8)
|
FGFR3 mutation
12ms
A deep-learning workflow to predict upper tract urothelial carcinoma protein-based subtypes from H&E slides supporting the prioritization of patients for molecular testing. (PubMed, J Pathol Clin Res)
Testing of the DL model on an independent cohort highlighted the importance to accommodate histological subtypes. Taken together, our DL workflow can predict protein-based UTUC subtypes, associated with the presence of targetable alterations, directly from H&E slides.
Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • FGFR3 (Fibroblast growth factor receptor 3) • FOXA1 (Forkhead Box A1) • GATA3 (GATA binding protein 3)
|
PD-L1 expression • FGFR3 mutation
12ms
Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial. (PubMed, Mol Cancer)
Post-surgery UC-score decreased in 97.7% of subjects. Overall, UI-Seek demonstrated robust performance and considerable potential for the early detection of UC.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3) • TERT (Telomerase Reverse Transcriptase) • ONECUT2 (One Cut Homeobox 2)
|
FGFR3 mutation • TERT mutation
|
UroVysion™ Bladder Cancer Kit (UroVysion Kit)
12ms
Clinical characteristics and prognosis of newly diagnosed multiple myeloma patients with FGFR3 gene mutations (PubMed, Zhonghua Xue Ye Xue Za Zhi)
The Cox proportional hazards model identified FGFR3 mutation as an independent risk factor for PFS and OS. FGFR3 gene mutation was an unfavorable independent prognostic predictor for NDMM.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR3 mutation
12ms
FOENIX-CCA2: A Study of TAS-120 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=407, Completed, Taiho Oncology, Inc. | Active, not recruiting --> Completed
Trial completion • Metastases
|
FGFR2 (Fibroblast growth factor receptor 2)
|
FGFR2 fusion • FGFR3 mutation • FGFR fusion • FGFR2 rearrangement • FGFR3 fusion
|
Lytgobi (futibatinib)
12ms
Comutations in FGFR3-Altered NMIBC Influence Recurrence/Progression (AUA 2024)
We predict that the diversity of response to FGFR inhibitors in FGFR3-altered NMIBC will be dependent on co-mutational patterns, and identified three co-alterations (CDKN1A, CDKN2A, TP53) that affect the HG-RFS and C-PFS of patients with FGFR3-altered tumors.
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • FGFR3 (Fibroblast growth factor receptor 3) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • CREBBP (CREB binding protein) • KDM6A (Lysine Demethylase 6A) • STAG2 (Stromal Antigen 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • E2F3 (E2F transcription factor 3) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A)
|
TP53 mutation • FGFR3 mutation • CDKN2A mutation • STAG2 mutation
|
MSK-IMPACT
1year
Integration of CD4+ T cells and molecular subtype predicts benefit from PD-L1 blockade in muscle-invasive bladder cancer. (PubMed, Cancer Sci)
These subtypes include luminal CD4+ Thigh , which demonstrated benefits from both immunotherapy and chemotherapy; luminal CD4+ Tlow , characterized by the highest level of fibroblast growth factor receptor 3 (FGFR3) mutation, thus indicating potential responsiveness to FGFR inhibitors; basal CD4+ Thigh , which could benefit from a combination of ICB and chemotherapy; and basal CD4+ Tlow , characterized by an immune suppression microenvironment and likely to benefit from transforming growth factor-β (TGF-β) inhibition. This immune-molecular classification offers new possibilities for optimizing therapeutic interventions in MIBC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
FGFR3 (Fibroblast growth factor receptor 3) • CD4 (CD4 Molecule) • TGFB1 (Transforming Growth Factor Beta 1)
|
FGFR3 mutation
1year
Artificial Intelligence (AI) Assisted Detection of FGFR3 Alterations In Bladder Cancer From Scanned Whole Slide Images (WSI) of H&E Sections (USCAP 2024)
We developed an effective AI system for detecting phenotypes associated with FGFR3 abnormalities that may be targetable by FGFR inhibitors. This system may allow cost and time savings in comparison to existing assays to screen bladder carcinomas for additional diagnostic testing.
FGFR3 (Fibroblast growth factor receptor 3) • TACC3 (Transforming acidic coiled-coil containing protein 3)
|
FGFR3-TACC3 fusion • FGFR3 mutation • FGFR3 S249C • FGFR3 Y373C • FGFR3 fusion • FGFR3 R248C
|
MSK-IMPACT